Senzime Q1 2026: Strong Margins, Better Cash Flow, and New U.S. Hospital Deals Keep Full-Year Growth Plan Alive

Senzime opened 2026 with a mixed but important first quarter, showing that the company is still moving forward even as short-term sales timing issues slowed reported growth. In its January-to-March 2026 update, the Swedish medtech company reported net sales of SEK 23.233 million, down 1% from the same period last year. However, on a currency-adjusted basis, sales rose 11%, suggesting that underlying demand remained healthy even though exchange-rate pressure and slower U.S. purchasing decisions weighed on the headline result. The company also said gross margin improved on an underlying basis, operating expenses stayed under control, and operating cash flow became notably stronger year over year. Management maintained its full-year targets, signaling confidence that the first-quarter slowdown was temporary rather than structural.

What happened in the quarter

Senzime’s first quarter was shaped by two opposing forces. On one side, the company continued to expand its installed base, increase disposable sensor usage, and deepen hospital relationships, especially in the United States. On the other side, it faced delayed capital purchasing processes in the U.S., a stronger Swedish krona, and the impact of tariffs, all of which reduced the strength of the reported numbers. The result was a quarter that looked softer on the surface than management believes it actually was underneath.

The company reported that U.S. sales came in at SEK 14.805 million, down 5% from the prior-year period, while sales in other markets totaled SEK 8.427 million, up 6%. Europe delivered one of the brighter regional performances, with revenue there rising 27% to SEK 4.857 million. By product category, disposables showed the strongest momentum. Total disposable sales rose sharply, while device and other sales were weaker, highlighting the broader trend inside Senzime’s business model: recurring sensor revenue is becoming more important, even when monitor placements fluctuate from quarter to quarter.

Revenue was flat on paper, but the mix mattered

Although total net sales declined slightly, the sales mix tells a more useful story. Disposables generated stronger growth than instruments, which matters because disposable sensors typically produce recurring revenue after a hospital adopts the company’s monitoring platform. In the U.S., disposables grew 32% year over year, while Europe posted 51% growth in disposables. That trend supports Senzime’s long-term thesis that once hospitals install the TetraGraph platform, sensor consumption can become the main driver of expansion.

Device sales, by contrast, were much softer. The company delivered 376 TetraGraph systems in the quarter, down from 443 in the first quarter of 2025. Senzime attributed that decline mainly to delayed capital buying decisions in the U.S., the launch of TetraGraph-as-a-Service as a complementary commercial model, and the normal volatility that can come with larger hospital orders. That explanation is important because it suggests demand may not have disappeared; rather, some decisions may simply have shifted later in the year or moved into different contract structures.

Margins improved underneath the surface

One of the clearest positives in the quarter was profitability at the gross-margin level. Senzime reported a gross margin before depreciation of 63.1%, versus 65.9% a year earlier. At first glance, that looks like a decline. But management also explained that the reported margin was pulled down by new U.S. tariffs, which reduced margin by 1.7 percentage points, and by the stronger Swedish krona, which reduced it by another 4.4 percentage points. Adjusted for those factors, the underlying gross margin reached 69.2%.

That adjusted figure is one of the most significant data points in the whole report. It shows that the core economics of the business are improving even though external factors distorted the headline number. Senzime also said it is pursuing innovation initiatives designed to lift gross margin above 70% over time. For investors and industry watchers, that matters because medtech companies with strong recurring revenue and expanding margins often gain more flexibility to invest in sales, product development, and market expansion.

Cost control helped limit the loss

Senzime’s operating expenses fell to SEK 35.562 million from SEK 37.297 million in the year-earlier quarter. Direct operating expenses were SEK 35.953 million, compared with SEK 36.429 million previously. The company said that strict cost control and a more efficient U.S. organizational structure contributed to this improvement. In other words, while revenue timing was messy, management did not let costs drift upward in response.

Operating profit for the quarter was SEK -25.886 million, compared with SEK -26.897 million in the first quarter of 2025. EBITDA came in at SEK -20.202 million versus SEK -20.838 million a year earlier. Profit after financial items improved to SEK -23.242 million from SEK -35.522 million, while net loss narrowed to SEK -22.512 million from SEK -34.662 million. Earnings per share improved to SEK -0.14 from SEK -0.27. Taken together, these numbers show that even in a quarter with uneven top-line timing, the company managed to improve several bottom-line measures.

Cash flow and liquidity showed progress

Another major theme in the report was cash flow. Senzime said operating cash flow improved by 33% year over year. The detailed cash-flow statement shows that cash flow from operating activities was SEK -23.029 million in the quarter, compared with SEK -32.299 million in the same period of 2025. That is still negative, but it is clearly less negative than before, which supports management’s claim that the business is moving in the right direction operationally.

Cash and cash equivalents at the end of March stood at SEK 55.353 million, compared with SEK 62.059 million a year earlier and SEK 73.975 million at the end of 2025. The company also disclosed that it had an unutilized credit facility of SEK 42.5 million. In addition, Senzime announced during the quarter that it had signed a credit facility totaling SEK 50 million with Crafoord, Segulah, several major existing shareholders, and DBT Capital, part of Noba Bank Group. This financing backdrop appears designed to support the company as it continues scaling and works toward profitability by year-end.

Management says the growth slowdown was temporary

The tone from management was cautious but confident. In the company’s first-quarter communication, CEO Philip Siberg said 2026 had started with improved margins and solid cash flow generation, but he also acknowledged delays in contract processes in the U.S. market. He linked the temporary slowdown to those contract delays and to the stronger Swedish krona. Even so, he said the company’s 2026 targets remained intact, with continued strong growth expected for the full year and profitability targeted by the end of the year.

That message is central to the quarter’s interpretation. Management is not presenting Q1 as a warning about weakening demand. Instead, it is framing the period as a timing issue that temporarily interrupted the visible growth path while underlying drivers stayed healthy. Whether that proves correct will depend heavily on execution in the next few quarters, especially in the U.S., where hospital purchasing cycles can be long and sometimes lumpy. Still, the company’s willingness to keep its annual targets unchanged suggests leadership believes the delayed business is still very much in play.

Big hospital relationships remained a major story

Even with softer near-term device sales, Senzime announced developments that point to continued traction with large hospital systems. During the first quarter, the company said it secured a major agreement with leading Ivy League hospitals in the United States. That deal included an initial installation of 60 next-generation TetraGraph systems and, when fully implemented, is expected to be used to monitor more than 10,000 patients per year. For a company of Senzime’s size, that kind of reference customer can be strategically important because it supports credibility, clinical adoption, and future expansion inside other health systems.

After the quarter ended, Senzime said it secured new contracts for delivery to hospitals within one of the world’s largest integrated healthcare systems. The company added that, if the rollout becomes system-wide, it would represent its largest deal in the United States to date. It also announced an expanded contract within a leading southeastern U.S. hospital system, including an additional 65 TetraGraph systems. These updates suggest that while some first-quarter purchasing decisions were delayed, commercial activity itself remained active and potentially meaningful.

The TGaaS model could reshape how Senzime sells

One of the most interesting strategic developments in the quarter was the launch of TetraGraph-as-a-Service, or TGaaS, in the U.S. market. This model is designed to simplify and shorten sales processes by allowing Senzime to place TetraGraph systems with customers while retaining ownership of the monitors. In return, the company charges a premium for the disposable sensors. Senzime said disposable sensors typically account for more than 90% of total customer revenue over time, making this model potentially attractive both commercially and financially.

The company signed its first two TGaaS agreements during the quarter, covering a total of 120 TetraGraph systems at hospitals within a leading Ivy League university system. That early adoption matters because it provides a real-world test of whether hospitals prefer a lower-friction entry model that focuses more on usage than upfront capital budgets. If TGaaS works as intended, it could help Senzime reduce one of the quarter’s biggest bottlenecks: delayed capital purchasing approvals. It could also support stronger margins over time because the recurring sensor business is typically more attractive than one-time hardware sales.

International expansion continued beyond the United States

Although the U.S. remains the company’s most important commercial market, Senzime also reported progress internationally. Europe posted solid growth during the quarter, and management highlighted that the next-generation TetraGraph is now being rolled out in Japan following market approval from the PMDA in December 2025. The company said first hospital contracts had already been secured there. In South Korea, the regulatory approval process for the next-generation TetraGraph is still ongoing.

That broader international picture is important because it diversifies the company’s revenue opportunity. A medtech company that depends too heavily on one market can be exposed to policy changes, procurement slowdowns, or currency swings. Senzime’s progress in Europe and Asia does not eliminate that risk, but it does widen the runway. If the company can translate regulatory wins into contract wins outside the U.S., it may be able to smooth out some of the quarter-to-quarter volatility that comes with American hospital buying cycles. This is an inference based on the company’s regional revenue data and market rollout updates.

Technology integration may strengthen adoption

Senzime also used the quarter to improve the practical side of product adoption. The company launched the TetraCom Connectivity Platform, which enables universal integration of the TetraGraph system directly into leading electronic medical record systems. In hospital settings, workflow integration can make a big difference. Even a clinically useful monitoring tool may face adoption hurdles if it creates extra steps for clinicians or sits outside the standard documentation process.

By connecting TetraGraph more directly into hospital systems, Senzime is aiming to make its technology easier to use and easier to scale. That may not show up immediately in quarterly sales, but it can strengthen the value proposition when hospitals compare competing monitoring solutions. Better integration can support stickier usage, stronger clinician compliance, and smoother expansion once a site has started using the product. This interpretation is consistent with the company’s stated goal of broadening adoption through platform integration.

Why the U.S. slowdown matters so much

The quarter made one thing very clear: the U.S. market remains the key swing factor in Senzime’s near-term performance. U.S. revenue represented SEK 14.805 million of the quarter’s SEK 23.233 million in total sales, meaning the region accounted for the majority of the company’s business. When purchasing delays happen there, they have an outsized effect on group-level growth. That is exactly what happened in Q1.

Still, the same market is also where the company appears to be building its most important commercial relationships. The Ivy League system agreement, the TGaaS contracts, the major integrated health system opportunity, and the southeastern hospital expansion all point back to the U.S. In that sense, the quarter did not show a company losing relevance in its main market. Rather, it showed a company whose commercial momentum may be running into the usual friction of hospital procurement. If those deals convert into wider deployment later this year, Q1 could look more like a pause than a turning point. This is an inference drawn from the company’s regional revenue breakdown and contract announcements.

What investors and industry readers should watch next

The next few quarters will likely revolve around five issues. First, readers should watch whether the delayed U.S. contracts start turning into confirmed revenue. Second, they should monitor whether the TGaaS model accelerates hospital onboarding and expands recurring sensor sales. Third, gross margin will be a major focus, especially whether the underlying near-70% level can remain intact despite tariffs and currency moves. Fourth, cash burn and liquidity will matter as the company pushes toward its stated year-end profitability goal. And fifth, international expansion in Japan and possibly South Korea could add useful growth support.

So far, management’s message is that the business fundamentals are improving even though the reported growth line briefly lost momentum. The data partly supports that view: adjusted sales growth was positive, disposables were strong, underlying margins improved, operating expenses fell, and cash flow got better. The biggest question is whether those positives can overcome the slower timing of large U.S. system placements. That answer will likely determine how the market judges the first quarter in hindsight.

Bottom line

Senzime’s first quarter of 2026 was not a breakout period in reported revenue, but it did offer several reasons for cautious optimism. The company showed stronger recurring-sales momentum in disposables, better underlying gross margins, tighter expense control, and improved operating cash flow. It also advanced major U.S. customer relationships, launched a new service-based commercial model, expanded financing flexibility, and continued international rollout efforts. The weak spot was clear: slower-than-expected U.S. purchasing processes reduced monitor placements and clouded the top-line picture. Yet management did not step back from its yearly ambitions.

Based on the official quarterly report and related company materials, the most balanced reading is that Senzime remains in expansion mode, but the path is uneven. The company appears to be improving the economics of the business while trying to make its sales engine more flexible through TGaaS and deeper hospital integration. If the delayed U.S. business converts and disposable sensor usage keeps rising, the company may still have a credible path to strong full-year growth and profitability by the end of 2026.

#Senzime #SNZZF #MedTech #EarningsReport #SlimScan #GrowthStocks #CANSLIM